晶泰控股(02228)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02228 晶泰控股

交易中 06-08 13:17:29

7.210

-0.280

-3.74%

最高7.300	最低7.010	成交量2,578万
今开7.170	昨收7.490	日振幅3.87%
总市值310.25亿	流通市值310.25亿	总股本43.03亿
成交额1.86亿	换手率0.60%	流通股本43.03亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02228","market":"HK","secType":"STK","nameCN":"晶泰控股","latestPrice":7.21,"timestamp":1780895849007,"preClose":7.49,"halted":0,"volume":25784089,"delay":0,"changeRate":-0.03738317757009349,"floatShares":4303000000,"shares":4303000000,"eps":0.03463961387480705,"marketStatus":"交易中","change":-0.28,"latestTime":"06-08 13:17:29","open":7.17,"high":7.3,"low":7.01,"amount":185955527,"amplitude":0.038718,"askPrice":7.22,"askSize":117000,"bidPrice":7.21,"bidSize":49000,"shortable":3,"etf":0,"ttmEps":0.03463961387480705,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1780906200000},"marketStatusCode":2,"adr":0,"listingDate":1718208000000,"exchange":"SEHK","adjPreClose":7.49,"openAndCloseTimeList":[[1780882200000,1780891200000],[1780894800000,1780905600000]],"volumeRatio":1.061815,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02228","defaultTab":"news","newsList":[{"id":"1167292028","title":"晶泰控股5月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1167292028","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167292028?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:37","pubTimestamp":1780562279,"startTime":"0","endTime":"0","summary":"2026年6月4日，晶泰控股发布截至2026年5月31日的月度证券变动报告。报告显示，公司法定股本保持在100,000,000,000股，面值每股0.00001美元，法定股本总额维持1,000,000美元，较上月无变化。公司已确认其截至2026年5月末的公众持股量符合法规要求。截至2026年5月末，公司股本总数維持不变，也未有股份回购或注销活动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640990891","title":"晶泰科技研发食品级口服肽Tensotide获美国Self-GRAS认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2640990891","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640990891?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:37","pubTimestamp":1780479465,"startTime":"0","endTime":"0","summary":"近日，全球领先的AI+机器人药物与材料研发平台企业晶泰科技（2228.HK）宣布，依托其AI多肽药物发现平台PepiX，公司已成功自主开发了一款关注血糖健康管理的创新口服食品原料——多肽Tensotide，获得美国Self-affirmedGRAS（一般认为安全）认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606033759113710.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02228","BK1617","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639600040","title":"晶泰控股(02228)：在自研创新多肽食品原料及孵化企业创新药管线方面取得两项突破性进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2639600040","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639600040?lang=zh_cn&edition=full","pubTime":"2026-05-31 19:05","pubTimestamp":1780225552,"startTime":"0","endTime":"0","summary":"智通财经APP讯，晶泰控股 发布公告，近期公司在自研创新多肽食品原料及孵化企业创新药管线方面取得两项突破性进展：1、晶泰依托AI多肽发现与优化平台PepiX自主开发的创新多肽食品原料 Tensotide，近日成功取得美国Self-GRAS认证。凭借此认证，Tensotide已具备合规进入美国食品市场及膳食补充剂的核心资质。这是继全球首款弥漫性胃癌靶向药 SIGX1094进入Ⅰ期临床后，希格生科进入临床的第二条创新药管线。晶泰享有该管线的商业化权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02228","BK1161","BK1574","159992","06978","BK1141","BK1617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639007846","title":"晶泰科技收到DoveTree第二笔付款，首个肿瘤项目推进至IND-enabling研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2639007846","media":"经济参考网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639007846?lang=zh_cn&edition=full","pubTime":"2026-05-31 18:21","pubTimestamp":1780222917,"startTime":"0","endTime":"0","summary":"日前，晶泰科技（2228.HK）宣布，与创新生物制药公司DoveTreeMedicinesUnusInc.的战略合作取得重要进展，并收到第二笔付款。公开资料显示，晶泰科技系全球领先的AI+机器人药物研发平台企业；DoveTree是一家创新生物制药公司，专注于开发针对重大未满足临床需求疾病的首创新药（first-in-class）疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605313755192039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IND","02228","BK1617","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639418526","title":"与DoveTree战略合作纵深推进，晶泰控股(02228)平台价值获业界与市场双重认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2639418526","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639418526?lang=zh_cn&edition=full","pubTime":"2026-05-29 13:41","pubTimestamp":1780033312,"startTime":"0","endTime":"0","summary":"5月27日，晶泰控股宣布，公司与DoveTree的合作进展理想，并已收到最终协议项下约定的第二笔付款1900万美元。而在去年与DoveTree达成的一项总订单规模约470亿港元的管线合作，正是晶泰控股“AI+机器人”平台价值迈入规模化兑现的具象化表现。强强联合步入下一发展阶段在此次晶泰控股最新发布的公告中，除了1900万美元合作付款到账外，公司与DoveTree的最新合作进展同样值得投资者高度关注。反观晶泰，DoveTree并非孤例。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"与DoveTree战略合作纵深推进，晶泰控股(02228)平台价值获业界与市场双重认可","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1617","BK1141","02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638468552","title":"晶泰控股(02228)与DoveTree的合作进展理想 再收1900万美元款项","url":"https://stock-news.laohu8.com/highlight/detail?id=2638468552","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638468552?lang=zh_cn&edition=full","pubTime":"2026-05-27 21:27","pubTimestamp":1779888457,"startTime":"0","endTime":"0","summary":"智通财经APP讯，晶泰控股 公布，集团与DoveTree的合作进展理想，部分商业价值潜力广阔的管线研发数据表现优异，其中一个泛癌种驱动高价值资产已率先进入临床申请前准备研究阶段，在初步生物学活性验证中展现出明确的靶点干预效应和优异的选择性窗口。据悉，于2025年6月底，深圳晶泰与DoveTree订立了最终协议。于2025年8月，集团已收到最终协议项下约定的5,100万美元的首付款。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446867.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02228","BK1141","BK1617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638753000","title":"晶泰控股(02228)：联合创始人自愿进一步延长禁售承诺","url":"https://stock-news.laohu8.com/highlight/detail?id=2638753000","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638753000?lang=zh_cn&edition=full","pubTime":"2026-05-25 20:25","pubTimestamp":1779711950,"startTime":"0","endTime":"0","summary":"智通财经APP讯，晶泰控股 发布公告，有关温书豪博士、马健博士及赖力鹏博士(创始人)各自实益持有的公司股份的禁售承诺届满日期自2025年6月12日自愿延长至2026年6月12日。公司已获告知，创始人为表达对公司长远价值的信心，已自愿进一步延长其禁售承诺届满日期，承诺自2026年6月12日起至2027年6月12日止额外十二个月内，不会出售彼等各自拥有实益权益的若干公司股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445704.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1617","02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113116148","title":"异动解读 | 晶泰控股盘中大跌5.01%，因出现大手卖出110万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1113116148","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113116148?lang=zh_cn&edition=full","pubTime":"2026-05-20 12:16","pubTimestamp":1779250619,"startTime":"0","endTime":"0","summary":"晶泰控股今日盘中股价大幅下挫，跌幅达5.01%，市场关注度显著提升。消息面上，该股在交易时段内出现一笔大手卖出交易，成交量达110万股，成交价为7.8港元，涉及资金约858万港元。这笔大额卖单的出现，可能引发了市场情绪的波动和部分投资者的跟风抛售，从而对股价形成了直接压力。从交易数据来看，该股当日最高价曾触及8.23港元，最低价则跌至7.8港元，与大手卖出的成交价一致，总成交量较为活跃。大额资金的集中离场往往是股价短期剧烈波动的重要诱因之一。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636304327","title":"“2026智通财经夏季路演大会”活动报名中 ！","url":"https://stock-news.laohu8.com/highlight/detail?id=2636304327","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636304327?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:06","pubTimestamp":1779069961,"startTime":"0","endTime":"0","summary":"5月28日，深圳前海。40+港股上市公司集中路演，与机构及高净值投资者面对面交流。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09696","02706","02411","02228","01907","01300","06682","02670","06636","02575","06090","00305","02659","LU0307460666.USD","02565","02652","06938","LU0287142896.SGD","01333","BK1100","HK0001040143.USD","06651","02526","08299","02726","00826","03858","LU0314109678.HKD","02729","02889","02675","01021","BK1171","VXUS","02685","03881","01396","00363","BK1155","01378","06051","02142","03317","02623","02650","00290","01384","02655","00400","00650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633687104","title":"【券商聚焦】中国银河：医药行业进入复苏周期 CXO板块景气度较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2633687104","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633687104?lang=zh_cn&edition=full","pubTime":"2026-05-08 09:00","pubTimestamp":1778202049,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国银河证券表示，2025年医药行业上市公司营业收入增长0.4%，归母净利润增长3.9%，扣非净利润下降4.1%，2026年一季度营业收入增长1.1%，归母净利润下降3.2%，扣非净利润增长2.0%。2025全年医药行业收入端小幅微增，主要系医保控费趋严，仿制药、耗材等集采常态化开展导致行业承压。2026年一季度创新药产业链高景气度延续，收入增幅扩大、非经常性损益占比下降，行业整体经营盈利能力提升，进入复苏上行周期。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980878","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01789","06160","BK0276","BK1585","LU0348767384.USD","BK1161","01530","02367","CXO","01099","06821","LU1719994722.HKD","03933","LU0348766576.USD","BK1197","LU2488822045.USD","LU2328871848.SGD","LU0634319403.HKD","601881","LU0417516902.SGD","BK1141","BK1593","BK0188","LU0588546209.SGD","BK1207","09926","LU0417516571.SGD","BK1583","LU1794554557.SGD","LU0640798160.USD","LU2476274720.SGD","02268","LU0348783233.USD","HK0000165453.HKD","LU0561508036.HKD","LU1961090484.USD","LU1251922891.USD","06881","02196","BK1588","LU0417516738.SGD","LU0307460666.USD","LU1303224171.USD","BK1500","LU1969619763.USD","09688","LU2778985437.USD","LU0348735423.USD","02228","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175745145","title":"晶泰控股更新4月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1175745145","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175745145?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:42","pubTimestamp":1778143360,"startTime":"0","endTime":"0","summary":"晶泰控股于2026年5月7日提交的股份变动月报表显示，截至2026年4月30日，公司股本结构保持稳定，已发行股份维持在4,303,371,761股，库藏股数量为0股。公司法定/注册股本总额为1,000,000美元，股本面值为每股0.00001美元，本月内并无增加或减少。根据月报表，公司在报告期内未进行新的股份发行、购回及注销，整体已发行股本总数与上个月相同。公司本次月报由晶泰控股董事温书豪博士签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176808963","title":"晶泰控股(02228) 斥资3.56亿元再购浦发银行结构性存款，12个月累计规模约8.73亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176808963","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176808963?lang=zh_cn&edition=full","pubTime":"2026-05-05 21:15","pubTimestamp":1777986957,"startTime":"0","endTime":"0","summary":"晶泰控股5月5日在港交所公告，旗下全资子公司QuantumPharm Limited已于2025年9月11日动用闲置资金人民币3.56亿元，认购上海浦东发展银行发行的两款低风险、保本浮动收益型结构性存款产品。连同过去12个月内已完成的六笔同类认购，公司在向浦发银行认购结构性存款上的累计交易金额达到约8.73亿元。值得关注的是，公司此前在认购浦发银行结构性存款时未及时发布公告。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633945627","title":"晶泰控股(02228)附属3.561亿元购买若干浦发银行结构性存款","url":"https://stock-news.laohu8.com/highlight/detail?id=2633945627","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633945627?lang=zh_cn&edition=full","pubTime":"2026-05-05 21:15","pubTimestamp":1777986905,"startTime":"0","endTime":"0","summary":"智通财经APP讯，晶泰控股 发布公告，于2025年9月11日，公司的附属公司QuantumPharm Limited以总对价人民币3.561亿元购买若干由上海浦东发展银行股份有限公司发行的结构性存款。浦发银行结构性存款为保本型产品，设有最低保证回报，另加浮动回报。发行人浦发银行为中国知名银行。因此，董事认为该等交易乃按一般商业条款进行，属公平合理，并符合公司及股东的整体利益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0278","600000","LU1934453819.USD","LU1979443071.USD","BK0187","02228","BK0028","SGXZ81163826.USD","BK0183","SGXZ49509284.SGD","BK1617","BK0015","BK0188","BK0086","LU1808992512.USD","LU0469268626.HKD","BK0012","BK0201","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631356119","title":"港股异动 | 晶泰控股(02228)尾盘涨逾8% 全球首创泛TEAD抑制剂亮相2026广东人工智能大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2631356119","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631356119?lang=zh_cn&edition=full","pubTime":"2026-04-29 15:17","pubTimestamp":1777447020,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，晶泰控股尾盘涨逾8%，截至发稿，涨8.14%，报9.17港元，成交额5.37亿港元。据悉，SIGX2649 为潜在first-in-class/best-in-class的泛TEAD抑制剂，在实体瘤治疗领域有广泛的药物市场。TEAD抑制剂作为靶向HIPPO通路的核心靶点，临床前数据显示，SIGX2649能有效抑制四种TEAD亚型，具备更强抗肿瘤活性、更低肾毒性，联用潜力突出，全球尚无同靶点药物上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436078.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ARTY","BK1141","BK4588","TEAD","02228","VXUS","BK4077","CHAT","AGIX","BK4585","BK1617","161631"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165941444","title":"异动解读 | 晶泰控股盘中大涨5.07%，年报利好兑现回调后迎来反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1165941444","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165941444?lang=zh_cn&edition=full","pubTime":"2026-04-29 14:39","pubTimestamp":1777444797,"startTime":"0","endTime":"0","summary":"晶泰控股今日盘中大涨5.07%，引起了市场的广泛关注。消息面上，公司此前披露的年度业绩表现强劲，收入同比增长逾两倍，并首次实现年度盈利。股价在业绩公布后因“利好兑现”及卖空压力经历了连续回调，今日盘中出现放量反弹，市场情绪因此得到修复。行业层面，生命科学工具和服务板块表现出现分化，同属AI制药赛道的部分公司股价也有所上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184562296","title":"异动解读 | 晶泰控股盘中大跌6.45%，年报利好兑现后承压，行业板块走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1184562296","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184562296?lang=zh_cn&edition=full","pubTime":"2026-04-24 09:56","pubTimestamp":1776995813,"startTime":"0","endTime":"0","summary":"晶泰控股今日盘中大跌6.45%，引起了市场的关注。消息面上，公司此前披露了年度业绩，收入同比增长逾两倍，并首次实现年度盈利。然而，股价在业绩公布后持续回落，呈现出“利好兑现”后的承压态势。同时，近期市场卖空活动活跃，空头成交金额占比较高，反映了部分资金的看空情绪。此外，从行业层面看，生命科学工具和服务板块整体表现疲软，晶泰控股在板块内领跌，行业环境的走弱也对股价构成了压力。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115956576","title":"晶泰控股（02228）2025年收入大增并实现扭亏 AI与药物研发协同驱动业务突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1115956576","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115956576?lang=zh_cn&edition=full","pubTime":"2026-04-17 21:01","pubTimestamp":1776430883,"startTime":"0","endTime":"0","summary":"于截至2025年12月31日止年度，晶泰控股收入达人民币8.03亿元，较上一年度的2.66亿元同比增长逾两倍。集团年内利润成功扭转2024年亏损15.15亿元的局面，实现人民币1.35亿元的正向收益，其中归属于公司权益持有人的利润为1.24亿元。主要收入来源包括药物发现解决方案和AI for Science智能化解决方案，两大板块分别实现418.9%和62.6%的增长，为整体业绩带来显著提升。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628209458","title":"晶泰控股(02228)建议采纳一项新股份计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2628209458","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628209458?lang=zh_cn&edition=full","pubTime":"2026-04-17 20:51","pubTimestamp":1776430267,"startTime":"0","endTime":"0","summary":"智通财经APP讯，晶泰控股(02228)公布，董事会建议采纳一项新股份计划，以进一步使公司董事及雇员的长期利益与公司的长期利益保持一致，并激励彼等持续推动公司的增长及发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1617","BK1141","02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627328922","title":"“AI制药第一股”晶泰科技进驻广州天河","url":"https://stock-news.laohu8.com/highlight/detail?id=2627328922","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627328922?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:30","pubTimestamp":1776252617,"startTime":"0","endTime":"0","summary":"4月15日，AI制药领军企业、“AI制药第一股”晶泰科技正式进驻广州天河的广电平云广场，同时与广州数字科技集团、广东创新投资发展有限公司完成战略签约，共同推动医疗数据与垂类大模型在生物医药领域深度应用。同日，平云OPC创新社区挂牌。晶泰科技由三位麻省理工学院的物理学家于2015年创立，是全球领先的以AI与机器人自动化实验技术驱动研发创新的平台型企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153706140328.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153706140328.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02228","01477","AGIX","AIPO","ARTY","BK1191","BK1617","BK1141","BK1574","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159698623","title":"异动解读 | 机构研报梳理AI制药核心价值，晶泰控股盘中大涨5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159698623","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159698623?lang=zh_cn&edition=full","pubTime":"2026-04-15 09:41","pubTimestamp":1776217282,"startTime":"0","endTime":"0","summary":"晶泰控股今日盘中大幅上涨5.48%，引起市场关注。消息面上，近期有机构发布深度研报，系统性地梳理了公司的核心价值。报告指出，晶泰控股在AI制药领域具有前瞻性布局和技术优势，其构建的“量子物理+AI+机器人实验”三位一体全链条技术闭环，以及较高的商业化项目兑现率，为公司基本面提供了有力支撑，这或是推动股价走强的主要原因。此外，公司在融资、实验效率及中长期打造AI for Science通用研发平台的目标方面表现突出，增强了市场对其未来增长潜力的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://www.xtalpi.com","stockEarnings":[{"period":"1week","weight":-0.091},{"period":"1month","weight":-0.1641},{"period":"3month","weight":-0.2555},{"period":"6month","weight":-0.2074},{"period":"1year","weight":0.5637},{"period":"ytd","weight":-0.2082}],"compareEarnings":[{"period":"1week","weight":-0.0088},{"period":"1month","weight":-0.0478},{"period":"3month","weight":-0.0309},{"period":"6month","weight":-0.0431},{"period":"1year","weight":0.0441},{"period":"ytd","weight":-0.0261}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"晶泰控股有限公司是一家主要从事为制药及材料科学等产业提供药物及材料科学研发解决方案及服务的控股公司。该公司主要经营两个业务。药物发现解决方案业务从事就新型药物发现工作为各类生物技术与制药公司和学术机构提供模块独立解决方案或与之合作。智能自动化解决方案业务从事提供固态研发服务及自动化化学合成服务。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.06643},{"month":2,"riseRate":0.285714,"avgChangeRate":0.016028},{"month":3,"riseRate":0,"avgChangeRate":-0.069153},{"month":4,"riseRate":0.666667,"avgChangeRate":0.048494},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.010585},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.023767},{"month":7,"riseRate":0.428571,"avgChangeRate":0.047576},{"month":8,"riseRate":0.5,"avgChangeRate":-0.032189},{"month":9,"riseRate":0.8,"avgChangeRate":0.065839},{"month":10,"riseRate":0.6,"avgChangeRate":0.092453},{"month":11,"riseRate":0.5,"avgChangeRate":0.05299},{"month":12,"riseRate":0.5,"avgChangeRate":-0.011625}],"exchange":"SEHK","name":"晶泰控股","nameEN":"XTALPI"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"晶泰控股(02228)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供晶泰控股(02228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"晶泰控股,02228,晶泰控股股票,晶泰控股股票老虎,晶泰控股股票老虎国际,晶泰控股行情,晶泰控股股票行情,晶泰控股股价,晶泰控股股市,晶泰控股股票价格,晶泰控股股票交易,晶泰控股股票购买,晶泰控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"晶泰控股(02228)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供晶泰控股(02228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}